These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 19932448)

  • 21. New strategies for combating multidrug-resistant bacteria.
    Wright GD; Sutherland AD
    Trends Mol Med; 2007 Jun; 13(6):260-7. PubMed ID: 17493872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daptomycin, a lipopeptide antibiotic in clinical practice.
    Weis F; Beiras-Fernandez A; Schelling G
    Curr Opin Investig Drugs; 2008 Aug; 9(8):879-84. PubMed ID: 18666036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of multiresistant Acinetobacter baumannii infections.
    Pachón J; Vila J
    Curr Opin Investig Drugs; 2009 Feb; 10(2):150-6. PubMed ID: 19197792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using sound for microbial eradication--light at the end of the tunnel?
    Harris F; Dennison SR; Phoenix DA
    FEMS Microbiol Lett; 2014 Jul; 356(1):20-2. PubMed ID: 24861483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
    Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
    Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view.
    Lynch AS
    Biochem Pharmacol; 2006 Mar; 71(7):949-56. PubMed ID: 16290174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial susceptibility of anaerobic bacteria in New Zealand: 1999-2003.
    Roberts SA; Shore KP; Paviour SD; Holland D; Morris AJ
    J Antimicrob Chemother; 2006 May; 57(5):992-8. PubMed ID: 16507560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms.
    Peppard WJ; Johnston CJ; Urmanski AM
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):83-99. PubMed ID: 18251666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antibiotic resistome: the nexus of chemical and genetic diversity.
    Wright GD
    Nat Rev Microbiol; 2007 Mar; 5(3):175-86. PubMed ID: 17277795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs.
    Lister PD
    Biochem Pharmacol; 2006 Mar; 71(7):1057-65. PubMed ID: 16316633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
    Jung R; Fish DN; Obritsch MD; MacLaren R
    J Hosp Infect; 2004 Jun; 57(2):105-11. PubMed ID: 15183239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to antimicrobial agents: an update.
    Rybak MJ
    Pharmacotherapy; 2004 Dec; 24(12 Pt 2):203S-15S. PubMed ID: 15585450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for multidrug-resistant bacteria.
    Giamarellou H
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):601-18. PubMed ID: 17009940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.